Recent Progress in Helicobacter pylori Treatment: Fighting Antibiotic Resistance and Beyond
Half of the world’s population carries Helicobacter pylori (H. pylori), a spiral-shaped bacterium that lives in the stomach. While many people have no symptoms, H. pylori is a leading cause of chronic gastritis, peptic ulcers, and gastric cancer—the third deadliest cancer globally. Eradicating H. pylori can prevent these diseases, but there’s a growing obstacle: antibiotic resistance.
For decades, doctors relied on proton-pump inhibitor (PPI)-based triple therapy (a PPI + two antibiotics like clarithromycin and amoxicillin). But today, resistance to clarithromycin, metronidazole, and levofloxacin exceeds 15% in all World Health Organization (WHO) regions—levels the WHO calls “alarming.” Triple therapy now fails in over 20% of cases, making it “unacceptable” by medical standards.
Thankfully, recent research offers new hope. From updated “quadruple” therapies to precision medicine and novel drugs, here’s a look at the latest advances in H. pylori treatment.
1. Bismuth-Containing Quadruple Therapy (BQT): The Current Gold Standard
BQT combines a PPI, two antibiotics, and bismuth—a heavy metal with a 300-year history of treating infections. Unlike antibiotics, bismuth works by:
- Reducing H. pylori’s ability to stick to stomach cells
- Weakening its defense against stomach acid and oxidative stress
- Boosting the effectiveness of other antibiotics
A 2019 meta-analysis of 25 trials (3,990 patients) found BQT eradicated H. pylori in 85.8% of cases—far higher than non-bismuth regimens (74.2%). Even in areas with high clarithromycin resistance (over 15%), BQT worked 2–3 times better than standard triple therapy.
Real-world studies back this up:
- Europe: An ongoing 10-year registry of 1,141 patients found BQT succeeded in 88% (intention-to-treat, ITT) and 94% (per-protocol, PP) of first-time treatments. 14-day courses worked better than 10-day (92% vs. 79% ITT).
- China: With high resistance rates, BQT using furazolidone (a less common antibiotic) cured 93–98% of patients in real-world settings. A 2019 trial found furazolidone-based BQT was also more cost-effective than clarithromycin-based BQT.
- Thailand: A pilot study of once-daily BQT (rabeprazole + levofloxacin + clarithromycin + bismuth) cured 94% of patients in 14 days—even those with clarithromycin or levofloxacin resistance.
BQT’s biggest advantage? H. pylori rarely develops resistance to bismuth. It’s safe, well-tolerated, and recommended as first-line treatment by global guidelines (Maastricht V, Chinese Fifth Consensus).
2. High-Dose Dual Therapy: Simpler, Fewer Antibiotics
For patients who hate taking multiple pills, high-dose PPI-amoxicillin dual therapy (HDDT) is a promising alternative. HDDT uses just two drugs—high-dose PPI (e.g., esomeprazole 40mg three times daily) and amoxicillin (750mg four times daily)—for 14 days.
Why does it work? Amoxicillin is one of the few antibiotics H. pylori rarely resists, and high-dose PPI keeps stomach acid low (critical for amoxicillin to work). A 2019 meta-analysis found HDDT had similar success rates to BQT (around 90% PP) but with fewer side effects (e.g., diarrhea, nausea).
A Chinese trial went further: adding bismuth to HDDT didn’t improve cure rates—except in smokers, who often have lower success with antibiotics. HDDT is now being tested in elderly patients, who are more sensitive to multiple drugs.
3. Vonoprazan: The Game-Changing Acid Blocker
Most H. pylori treatments rely on PPIs to reduce stomach acid. But PPIs have limits: they’re less effective in people with certain gene types (CYP2C19) and wear off quickly.
Enter vonoprazan—a “potent acid blocker” approved in Japan in 2015. Unlike PPIs, vonoprazan:
- Works immediately (no activation needed)
- Lasts longer (half-life of 9–12 hours vs. 1–2 hours for PPIs)
- Keeps stomach pH above 4 for 20+ hours a day—ideal for antibiotics
Japan’s experience with vonoprazan is dramatic. From 2013 to 2018, use of PPIs (like lansoprazole) in H. pylori treatment plummeted from 81.8% to 3.4%, while vonoprazan rose to 95.5%. Eradication rates jumped from below 80% to over 90% in first-line therapy.
Vonoprazan works especially well against clarithromycin-resistant strains—a big win since clarithromycin resistance is a top cause of treatment failure. Even in third-line therapy (after two failed attempts), vonoprazan + sitafloxacin (a new antibiotic) cured 93% of patients—including those resistant to sitafloxacin.
A 2019 study even found vonoprazan + amoxicillin (dual therapy) worked as well as triple therapy—simpler and with fewer antibiotics.
4. Tailored Therapy: Precision Medicine for H. pylori
The best treatment for H. pylori depends on which antibiotics it’s resistant to. But traditional culture-based testing takes days and requires a stomach biopsy.
New PCR-based tests (like DPO-PCR, GenoType HelicoDR) change the game. These tests detect H. pylori and its resistance genes (e.g., for clarithromycin) from a simple stool or breath sample—results in hours.
A 2019 Korean study found tailored therapy using DPO-PCR cured 90% of patients—better than empirical triple therapy (76%). A French trial of 526 patients found PCR-guided therapy had a 15% higher success rate than standard care and reduced new resistance.
Tailored therapy is especially useful in high-resistance areas (e.g., Korea, China). It’s faster, more precise, and helps preserve antibiotics for future use.
5. Adjuvants: Probiotics and Vitamins
No treatment is perfect—antibiotics often cause side effects (diarrhea, nausea) that make patients stop taking them. Probiotics (friendly bacteria) and vitamins can help:
- Probiotics: Strain-specific probiotics like Saccharomyces boulardii and Lactobacillus reduce side effects and boost eradication rates. A 2019 meta-analysis found S. boulardii added to triple therapy increased cure rates by 10% and cut diarrhea by 50%. Probiotics also protect the gut microbiome, which antibiotics can disrupt.
- Vitamins: Vitamins C and E act as antioxidants, reducing H. pylori-induced inflammation and stomach cancer risk. A 22-year study of 3,365 high-risk patients found H. pylori treatment + vitamin C/E/selenium reduced gastric cancer deaths by 50%. Vitamin D levels are also linked to better eradication—patients with low D are 2x more likely to fail treatment.
But caveats apply: Probiotic effects are strain-specific (not all work), and vitamin doses matter (high-dose C/E is more effective). More research is needed to standardize their use.
6. Future Directions: Novel Drugs and Global Databases
Scientists are also targeting H. pylori’s unique biology to develop new drugs:
- Flavodoxin inhibitors: These compounds block a protein H. pylori needs to survive in the stomach. They’re effective against multidrug-resistant strains and cured 60% of infected mice.
- HsrA inhibitors: Four natural compounds (apigenin, chrysin, kaempferol, hesperetin) target a key H. pylori regulator. Chrysin even works synergistically with clarithromycin—great for resistant strains.
To track treatment trends and resistance, the European Helicobacter and Microbiota Study Group launched a 10-year registry (Hp-EuReg). It collects data on real-world treatment, eradication rates, and side effects—critical for updating guidelines.
Conclusion: A New Era of H. pylori Treatment
The days of “one-size-fits-all” H. pylori therapy are over. Today, the best approach depends on:
- Local antibiotic resistance rates
- Patient’s age, genetics, and lifestyle (e.g., smoking)
- Access to tests (PCR, culture)
BQT remains the “go-to” for most patients, but vonoprazan and tailored therapy are changing the game for resistant strains. HDDT offers a simpler option for those who hate pills, and probiotics/vitamins help with side effects and long-term health.
The biggest takeaway? We’re no longer just “treating” H. pylori—we’re outsmarting it. With ongoing research into novel drugs and precision medicine, we can stay ahead of antibiotic resistance and save more lives from gastric cancer.
For now, if you’re diagnosed with H. pylori, talk to your doctor about the best option for you. The future of H. pylori treatment is personal—and promising.
Yi Hu, Yin Zhu, and Nong-Hua Lu are from the Department of Gastroenterology at The First Affiliated Hospital of Nanchang University, China. This work was funded by the National Natural Science Foundation of China and the Graduate Innovation Fund of Jiangxi Province. No conflicts of interest were declared.
doi.org/10.1097/CM9.0000000000000618
Was this helpful?
0 / 0